Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of KN060 for prevention of venous thromboembolism after unilateral total knee arthroplasty
CTR20261025Phase 3Active
- Sponsor
- Alphamab Oncology
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lofacimig in venous thromboembolism (VTE), sponsored by Alphamab Oncology. Started May 2026; status: active.
02
Drugs
lofacimig
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on CTR20261025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261025.